EcoDrugPlus

Proteasome (Prosome, Macropain) Subunit, Beta Type 7

Ensembl ID : ENSMSIG00000000365
Gene Symbol: PSMB7
1 Cross references
233 Possible Orthologues:

Proteasome (Prosome, Macropain) Subunit, Beta Type 8 (Large Multifunctional Peptidase 7)

Ensembl ID : ENSMSIG00000010986
Gene Symbol: PSMB8
1 Cross references
235 Possible Orthologues:

Proteasome (Prosome, Macropain) Subunit, Beta Type 9 (Large Multifunctional Peptidase 2)

Ensembl ID : ENSMSIG00000011042
Gene Symbol: PSMB9
1 Cross references
227 Possible Orthologues:

Proteasome (Prosome, Macropain) Subunit, Beta Type, 11

Ensembl ID : ENSMSIG00000016415
Gene Symbol: PSMB11
1 Cross references
242 Possible Orthologues:

Proteasome Subunit Alpha 1

Ensembl ID : ENSMSIG00000028812
Gene Symbol: PSMA1
1 Cross references
269 Possible Orthologues:

Proteasome Subunit Alpha 2

Ensembl ID : ENSMSIG00000013613
Gene Symbol: PSMA2
1 Cross references
240 Possible Orthologues:

Proteasome Subunit Alpha 5

Ensembl ID : ENSMSIG00000019197
Gene Symbol: PSMA5
1 Cross references
223 Possible Orthologues:

Proteasome Subunit Alpha 6

Ensembl ID : ENSMSIG00000018324
Gene Symbol: PSMA6
1 Cross references
245 Possible Orthologues:

Proteasome Subunit Alpha 7

Ensembl ID : ENSMSIG00000016080
Gene Symbol: PSMA7
1 Cross references
165 Possible Orthologues:

Proteasome Subunit Alpha 8

Ensembl ID : ENSMSIG00000006470
Gene Symbol: PSMA8
1 Cross references
212 Possible Orthologues:

Protein Arginine N-Methyltransferase 5

Ensembl ID : ENSMSIG00000016312
Gene Symbol: PRMT5
1 Cross references
213 Possible Orthologues:

Protein Kinase C, Alpha

Ensembl ID : ENSMSIG00000022965
Gene Symbol: PRKCA
1 Cross references
304 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).